Director/PDMR Shareholding

RNS Number : 8723M

Futura Medical PLC

18 September 2019

 

Directors' / PDMR Dealing and Grant of Options

18 September 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announces that on 17 September 2019 it made its annual grant of options over a total of 1,400,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to employees and Directors, of which 650,000 options were granted to Directors and PDMRs as detailed below.

Director	Number of options granted	Exercise price	Exercise period	Total number of options held following notification	Total number of Ordinary Shares held
J H Barder	250,000	31p	1 Oct 2021 - 30 Sep 2026	1,750,000	1,085,972
A Hildreth	200,000	31p	1 Oct 2021 - 30 Sept 2026	400,000	142,857
K W James	200,000	31p	1 Oct 2021 - 30 Sept 2026	800,000	299,581

Of the total 1,400,000 options, 1,281,935 were granted under the Futura Medical plc Enterprise Management Incentive Scheme, and 118,065 were granted under the unapproved scheme.

The main vesting condition of the options is that the Director/PDMR/employee remains employed with the Company as at the date of exercise.  Further disclosures are contained in the tables below. 

 ENDS

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]

Nominated Adviser and Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel: [phone]

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with a 450 patient open label extension.  FM57 is progressing on track, with headline data expected by the end of 2019.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	James Barder
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Grant of options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) Exercise price of 31 pence   250,000
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	17 September 2019
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Angela Hildreth
2	Reason for the notification
a)	Position/status	Finance Director and Chief Operating Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Grant of options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) Exercise price of 31 pence 200,000
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	17 September 2019
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ken James
2	Reason for the notification
a)	Position/status	Executive Director and Head of R&D
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.2 pence each GB0033278473
b)	Nature of the transaction	Grant of options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) Exercise price of 31 pence 200,000
d)	Aggregated information -         Aggregated volume -         Price	N/A single transaction
e)	Date of the transaction	17 September 2019
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHLLFSRALITLIA